Merck 3Q profit down 35 pct. amid competition from generics

29-10-2013 Philly.comComments (0)

Merck & CoPharmaceuticalSingulair

Generic competition continues to hammer asthma and allergy pill Singulair, cutting sales 53 percent to $280 million. The drug brought in $5.5 billion a year until its patent expired in August 2012 and cheap copycat versions flooded the market. The ...

Read more on Philly.com

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top